ODI Pharma

First quarter (2025-07-01 - 2025-09-30)

• The Group's net sales amounted to SEK 5,968,143 (143,793).
• The Group's profit after financial items amounted to SEK -37,027 (-1,468,183).
• Result per share amounted to SEK -0.00 (-0.10).*
• The solidity as of 2025-09-30 was 4% (9%).**

* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 30th of September 2025, amounted to 18,330,419 (15,220,000) shares. The result per share based on the average number of shares of 18,330,419 (15,220,000) amounts to SEK -0.00 (-0.10) for the first three months 2025-07-01 to 2025-09-30.

** Solidity: Equity divided by total capital.

Highlights during the fourth quarter

• No significant highlights during the period.

Highlights after the end of the period

• ODI Pharma announced an operational update following recent improvements in its commercial performance. Strategic and practical measures implemented in recent quarters have begun to show clear results, supported by a more stable regulatory environment and smoother product flows into the Polish market.

"The groundwork laid in recent quarters is now showing clear results, with stronger sales, better delivery performance, and growing order volumes. ODI Pharma is entering this fiscal year with renewed confidence and a clear focus on profitable, long-term growth."- Volker Wiederrich, Chairman of the Board

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com  

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.